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Breast cancer is the second leading cause of cancer-associated deaths among 
women in the United States, with greater than 40,000 women dying each year from this 
disease.  While specific DNA mutations have been shown to be involved in the 
development of breast cancer, it is the cooperation and collaborative effects of multiple 
mutations and genetic alterations that leads to carcinogenesis.  The accumulation of 
mutations suggests that accurate models cannot focus on a single mutation but rather the 
interplay of several mutations.  Thus, it has becoming increasingly apparent that the 
successful treatment of breast cancer will rely upon understanding how multiple 
pathogenic mutations and pathways interact.   Each year, approximately 11,000 new 
cases of breast cancer will harbor both a TP53 and PIK3CA mutation, the two most 
common somatic mutations in nonhereditary breast cancer.   The implementation of gene 
targeting to develop a panel of somatic knock-in isogenic cell lines harboring both a 
PIK3CA and a TP53 mutation in human breast epithelial cells provides a model with 
multiple pathogenic mutations.   The model more accurately demonstrates the progressive 
genetic events leading to breast carcinogenesis.  The development of a closely related 
panel of isogenic cell lines will all phenotypic transformations to be attributed to 
dysregulation of an entire pathway, a specific mutation, or a clonal variation.  
Furthermore it allows for the identification of potential therapeutic biomarkers, targets, 
and provides new mechanistic insight between the two most somatically mutated 
pathways in breast cancer.   
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Breast Cancer and Genetics Overview 
 
Breast cancer is the second most common cause of cancer-associated death 
among women in the United States.  Approximately 1 in 8 women will be diagnosed with 
breast cancer in the span of their lifetime.  In 2013, the American Cancer Society 
estimated 232,340 new cases of invasive breast cancer and 64,640 new cases of non-
invasive (in situ) breast cancer were diagnosed in women in the US.  Approximately 
39,620 of these cases resulted in death (1),   Human cancer develops due to the 
accumulation and selection of rare subvariant mutations in oncogenes and tumor 
suppressor genes. The acquisition and clonal expansion of these subvariants promotes 
increasingly aggressive phenotypes, which lead to the development of cancer (2). 
Statistical analyses suggest that, on average, an individual tumor contains approximately 
80 mutations with less than 15 of these being responsible for driving the initiation, 
progression, or maintenance of the tumor.  Recently, PIK3CA and TP53 were identified 
as the most mutated oncogene and tumor suppressor gene, respectively, in human breast 
cancer (3, 4).   
 In 1991, it was suggested that underlying genetic instability was absolutely required 
for the accumulation of multiple mutations in cancer (5).  The link between genetic 
instability and the development of cancer was repeatedly established until in 2011, 
genomic instability and increased mutational rates were officially recognized as new 
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enabling hallmarks of carcinogenesis (6).  It is important to distinguish here the 
difference between the genomic instability of a cell line versus the mutational state of a 
cell line.  By definition, genomic instability refers to the rate of mutational accumulation, 
and does not imply that a cell line is genetically unstable.  The existence of mutations in a 
cell line represents the static state and does not provide information on the occurrence of 
acquired mutations (7).  It has been previously shown that many aneuploid breast cancers 
have cell-to-cell variability in copy number, suggesting a carcinogenic component of 
genomic instability (8).  
 Often, the accumulation of mutations is accelerated by compromising checkpoints 
in the cell cycle that normally monitor damage within the cell.  TP53, known as the 
“guardian of the genome”, plays an essential role in maintaining the genome integrity.  
The loss of TP53 leads to increased genomic insult and a higher rate of mutational 
accumulation. These “driver” mutations thus lend themselves as potential markers for 
prognosis, and are also ideal targets for therapy, given their importance for the growth 
and viability of cancer cells.  Recently, the gene PIK3CA, was found to be frequently 
mutated in many cancer types, with a high frequency of about 25-30% in breast (3) and 
colorectal (9) cancers. Hotspot mutations in TP53 and PIK3CA may lead to chromosomal 
loss of other tumor suppressor genes and/or important regulatory genes due to genomic 
instability.  The instability and potential allelic loss of these genes significantly increases 
the potential for carcinogenesis and the development of cancer.         
TP53 
p53 was the first identified in 1979 as a cellular protein tightly associated with the simian 
virus 40 large T protein (SV40LT).  SV40LT, a nonstructural product of the viral 
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genome, played an important role in the oncogenic capacity of SV40 (10).  The strong 
association with p53 led to several studies identifying it as a tumor antigen and 
postulating that p53 might be a cellular oncogene product linked to the viral 
transformation process (11, 12).   In the early 1980s, several isolates of p53 cDNA clones 
were studied and found to transform cells in combination with the Ras oncogene (13, 14).  
Therefore, p53 was initially and incorrectly established as an oncogene.  However, in the 
late 1980s several studies demonstrated mutations in both alleles were required for tumor 
formation and p53 was re-identified as the first tumor-suppressor protein (15-18).  
TP53 encodes p53, a 53 kDa nuclear phosphoprotein expressed at a biologically 
latent state in all cells.   In 1992, three groups of scientists showed that the p53 protein 
acts as a transcription factor and binds to specific DNA sequences or response elements 
(REs).  As a transcription factor, p53 initiates three different processes that define it as a 
tumor suppressor;  First, p53 initiates cell cycle arrest through the regulation of p21 and 
cdc25c (19). Secondly, p53 regulates the apoptotic genes bax, puma, noxa, and apaf-
1(20).  Lastly, p53 can initiate cell senescence leading to a terminal state of replication 
(20).    Through the transcriptional regulation of these three pathways, p53 has been 
shown to play a central role in protecting against DNA damage and maintaining genomic 
integrity.  As part of its central role, p53 monitors and governs the G1/S phase checkpoint 
of the cell cycle.  Upon DNA damage, ATM kinase activates and upregulates p53, which 
acts as a transcription factor and activates the cyclin-dependent kinase inhibitor, p21 (21).  
p21, in turn, stalls the cell cycle and allows the cell time for DNA repair, thus preventing 
the replication of damaged chromosomes.  Alternatively, if DNA is beyond repair, p53 
activates members of the Bcl-2 family to carry out programmed cell death, also known as 
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apoptosis (22).  In the absence of stress, wild-type p53 is strongly regulated to allow 
normal cellular functions to process.  MDM2, a key negative regulator, binds to the 
transactivation domain of p53 and ubiquitylates the protein, targeting it for degradation 
(23). When functioning properly, p53 acts as a critical brake on tumor development. 
Therefore, it is not surprising that 50% of all cancers harbor a TP53 mutation (24).  In the 
absence of p53, both cell cycle arrest and apoptosis are compromised, presumably 
allowing cancer cells to progress. 
TP53 is the most commonly mutated tumor suppressor gene in breast cancer and 
is most often associated with the triple negative subtype (25, 26). Approximately 70% of 
TP53 mutations found in breast cancer are attributed to inactivating point mutations with 
>90% of these occurring in the DNA binding domain, termed contact mutations.  Contact 
mutations disrupt p53’s ability to bind to DNA and function as DNA modulator (27, 28).  
The majority of contact mutations occur at codon 248 with the R248W mutant being 
associated with the highest rate of mortality (29, 30).  While mutation of p53 generally 
results in the inactivation of tumor suppressor function, missense mutants also confer a 
dominant-negative and/or gain-of-function phenotype, which is highly tissue specific (31, 
32).  While most tumor suppressor genes require biallelic inactivation, TP53 hotspot 
mutations impart a dominant-negative and/or gain-of-function effect.  p53 functions as a 
tetramer, however in the presence of a dominant-negative mutant, it and the wild-type 
protein form functionally inactive hetero-oligomers (33, 34). Although the concept of 
mutant p53 gaining oncogenic properties, commonly referred to as gain-of-function 
(GOF), was first suggested in 1984, it still remains a controversial and poorly understood 
mechanism (25, 35).  In 1995 Dittmer et al. was the first to distinguish a gain of function 
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phenotype in the absence of the dominant negative effect.  By introducing a mutant p53 
allele into a mouse model devoid of all endogenous p53 protein, new acquired 
phenotypes were attributed to the presence of the mutant protein (36).  Dittmer et al 
concluded that mutant p53 expression conferred a growth advantage in the absence of 
endogenous wild-type p53 protein.  For the next two decades, it was shown that mutant 
p53 exhibited a variety of transformative phenotypes in a variety of models;  increased 
DNA synthesis and proliferation (37, 38), cell survival (39), chemoresistance (40), 
abnormal centrosome checkpoints (41), gene amplification (42), stem cell characteristics, 
migration, invasion, and metastatic abilities (43). 
 
PIK3CA 
Phosphatidylinositol 3-kinases (PI3Ks) were discovered in the 1980s and are 
comprised of a family of heterodimeric lipid kinases consisting of a regulatory subunit 
(p85) and a catayitic component (p110), which participate in a diverse set of cellular 
signaling pathways.  There are several isoforms and classes of known PI3Ks. The 
majority of PI3Kinases are organized under three main classes (I, II, and III) based on 
their structure, substrate, specificity, and regulation.  Briefly, Class I PI3Ks are divided 
into two subfamilies, A and B depending on the receptors to which they couple (44).  
Class 1A consists of a p85 regulatory subunit and a p110 catalytic subunit (45). The p85 
subunit is crucial in mediating the activation of class 1As by receptor tyrosine kinases 
(RTKs).  Alternatively, class 1Bs consist of a p101 regulatory subunit and a p110γ 
catalytic subunit.  Although the catalytic subunits share extensive homology, the p101 is 
distinct from p85 proteins and is activated by G-protein-coupled receptors (GPCRs).  
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Under normal cellular conditions, Class I PI3Ks are responsible for the phosphorylation 
of phosphatidylinositol 4,5-bisphosophate (PIP2) to phosphatidylinositol 3,4,5-
bisphosophate (PIP3) at the cell membrane (46).  Class II PI3Ks consist of only a p110-
like catalytic subunit and preferentially phosphorylates phosphatidylinositol and to a 
lesser extent, phosphatidylinositol-4-P (PI-4-P) (47).  Lastly, class III PI3Ks consist of a 
single member known as Vacuolar Protein-sorting Defective 34 (Vps34).  Relatively little 
is known about the specific functions of Vps34, however, it was recently implicated that 
the Vps34 is involved in the regulation of mTOR and may be crucial for controlling cell 
growth (44, 48, 49).  The majority of our understanding of PI3K signal transduction is 
based on studies of class I PI3Ks, which are involved in many important physiological 
processes. 
As mentioned previously, Class I PI3Ks are responsible for the phosphorylation 
of PIP2 to PIP3.  Upon growth factor stimulation, the regulatory protein p85 binds to 
phospho-motifs of RTKs, relieving its inhibitory effect over p110.  There are three 
different isoforms of the p110 subunit, p110α, p110β, and p110δ which are encoded by 
PIK3CA, PIK3CB, and PIK3CD, respectively.   Activated p110 catalyzes the conversion 
of PIP2 to PIP3, which acts as a lipid second messenger and binds to the pleckstrin-
homology (PH) domain of many downstream molecules (50).  The principle target of 
PIP3 is the protein serine/threonine kinase AKT (or PKB), which leads to the subsequent 
intracellular cascade of phosphorylation and regulation of a range of cellular functions.  
Activation of the AKT pathway leads to the control of 4 main cellular processes: (1) cell 




The p110α catalytic subunit of the Class IA PI3Ks is encoded by the gene 
PIK3CA and is one of the most highly mutated oncogenes in human cancers.    In 2004, 
PIK3CA was identified as the most mutated oncogene in human breast cancer (3). High 
mutational frequencies of PIK3CA have been reported in colorectal (9), breast (51), and 
liver cancers (52) while lower rates of mutation have been described in many other 
human malignancies including ovarian (53), lung (9, 52), gastric (9, 52, 54, 55), and brain 
cancers (56-58). In breast cancer, PIK3CA has a reported overall mutational rate of 25%, 
with more than 80% being attributed to “hot spot” regions within exon 9 of the helical 
domain and exon 20 of the catalytic domain (3).  These three mutations, E542K and 
E545K in exon 9 and H1047R in exon 20 lead to increased PI3K catalytic activity 
through the activation of the PI3K/AKT/mTOR pathway.  This increased activity results 
in cellular transformation through growth factor- and anchorage-independent cellular 
proliferation (59, 60). Studying the effects of these mutations in colorectal cells (61-63), 
breast epithelial cells (60, 64), and chicken embryo fibroblasts (65, 66) have illustrated a 
direct connection between these mutations and carcinogenesis.   
Through crystallographic and biochemical methods, it has been determined that 
the probable oncogenic mechanism of the E545K mutation is the disruption of an 
inhibitory charge-charge interaction between p110α and the N-terminal SH2 domain of 
the p85 regulatory subunit (67).  It has been previously proposed that the oncogenic 
mechanism of the E542K mutation is similar to E545K, exhibiting a change in the 
interaction of p110α with the p85 regulatory subunit.   The proposed oncogenic 
mechanism of the H1047R mutation differs from the exon 9 mutations.  The H1047R 
mutation increases the binding affinity of p110α for the negatively charged 
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phosphatidylinositol substrate leading to increased activity and transforming potential 
(68).   
Along with the above transformative changes in cells with increased PI3K 
signaling, aberrant PI3K signaling has also been linked to resistance of cells in preclinical 
models to a number of targeted and cytotoxic cancer therapies, including trastuzumab and 
paclitaxel resistance in human breast epithelial cells harboring PIK3CA mutations (60, 
69).   Clinically, the presence of PIK3CA mutations has been linked to both favorable 
(70, 71) and unfavorable (72, 73) patient prognosis, and it has also been reported that 
exon 9 mutations have a less favorable prognosis than exon 20 mutations in breast cancer 
(74).  The reasons for these conflicting data are not clear, but likely reflect limited sample 
sizes and difference in treatment regimens between the various studies.  Changes in 
activity have been associated with increased resistance to chemotherapeutics in breast 
malignancies.   
 
Clinical Occurrence of Mutant PIK3CA and TP53 
In 2011, a clinical study genotyped 120 primary breast tumors and determined the 
combined frequency of mutations in both TP53 and PIK3CA to be approximately 5.3% 
which accounts for approximately 11,000 cases of breast cancer per year (75).    As 
mentioned earlier, approximately 50-60% of breast cancers contain either a TP53 or 
PIK3CA mutation, while only 5.3% of these contain both.  The low frequency compared 
to the individual mutation rates can be attributed to hormone receptor expression.  TP53 
is commonly associated with ER-/PR- breast cancers, while PIK3CA is often associated 
ER+/PR+.  However, the combined frequency of TP53 and PIK3CA was relatively high 
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when compared to other combined frequencies in the study, which exhibited numbers 
closer to 1.3% (75). It is also important to note that TP53 can often be mutated in late 
stage disease, for which mutational data on metastatic samples is limited.   
In general, when using systemic therapies to treat cancer, combining therapies is a 
more effective strategy for eliminating potential drug resistance rather than the use of 
single agents. The importance of studying mutations in the context of one another was 
demonstrated by Di Nicolantanio and colleagues in 2010, where they showed that 
PIK3CA mutations, while sensitive to rapamycin individually, became resistant in the 
presence KRAS or BRAF mutations (76).  Di Nicolantonio et al. demonstrated the 
importance of studying molecular markers in the context of one another and the vastly 
different phenotypes that can arise in the presence of additional mutations.  While 
specific oncogenic DNA mutations help to provide insight to the development and 
treatment of breast cancer, it is the cooperation and collaborative effect of these 
mutations that leads to carcinogenesis.  The accumulation of mutations suggests that 
accurate models cannot focus on a single mutation but rather the interplay of several 
mutations.   It is becoming increasingly apparent that the successful understanding and 
treatment of breast cancer will rely on targeting several oncogenic DNA mutations.  
Therefore, the rationale for targeting both PIK3CA and TP53 hotspot mutations becomes 
immediately obvious.  
This study provides new insight into how targeting separate but cooperating 
pathways increases the hallmarks of cancer.  The generation of a panel of different 
mutations in a relatively isogenic system allows for the examination of these mutations 
singly and in combination.  The investigation of two different mutations within each of 
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the genes within a relatively normal background provides a controlled model for 
investigating these mutations.  Furthermore, the development of completely independent 
clones harboring the same mutations allows for the direct comparison of phenotypic 
similarities and differences.  This allows us to attribute whether a transformative property 
is due to the combination of a two mutated genes, the dysregulation of a specific gene 
regardless of mutation type, a specific mutation type, a clonal variant, or any permutation 
of these characteristics. This panel provides a stronger understanding of the hallmarks of 
cancer and the role two of the most frequently mutated genes in cancer can potentially 




MCF10As harboring an isogenic TP53 R248W 
hotspot mutation 
Introduction 
TP53 encodes p53 and is one of the most well-studied tumor suppressor genes. 
Among its many functions, p53 plays a central role in apoptosis, cell cycle arrest and 
maintaining genomic integrity (15, 16).  Normally, p53 acts as a critical cellular 
checkpoint monitor in response to stress such as DNA damage.  This function prevents 
cells with aberrant or damaged DNA from proceeding through the cell cycle, allowing 
time to correct damaged DNA, or induce apoptosis if DNA cannot be repaired.  This 
critical role thus prevents cells with altered DNA from inappropriate cell division.  
Although TP53 is one of the most well described tumor suppressor genes, the 
mechanisms of many of its functions have not been fully elucidated.  In particular, p53’s 
role in maintaining genomic stability remains incompletely understood.  It is well known 
that in the absence of normal p53 function, downstream effectors such as p21 are crippled 
and can no longer prevent aberrant cell cycling in response to DNA damage(19).  
However, this suggests that lack of p53 function is not directly responsible for genome 
instability, but instead that damaged DNA is allowed to inappropriately propagate 
through cell division if p53 function is absent(77).  This would also suggest that 
increased cell cycling would produce more opportunities for DNA errors, and thus the 
absence of p53 function in this instance would allow cells with DNA errors to propagate 
rapidly and lead to an increased potential for producing oncogenic changes.  However, 
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many human cancers have low proliferation rates, yet still display genomic instability and 
aneuploidy(78).  In addition, seminal studies have demonstrated that loss of TP53 has 
distinct functional consequences compared to TP53 missense mutations (30, 79), yet both 
types of alterations are found in human cancers.  Thus, mechanisms of how genomic 
instability and aneuploidy arise may differ in cancer cells with homozygous loss of TP53 
versus those with heterozygous missense mutations. 
In this study, we sought to elucidate the mechanism of genomic instability 
specifically associated with TP53 loss.  We approached this via genome editing using the 
non-cancerous human breast epithelial cell line, MCF10A, and comparing p53 null cells 
to isogenic cells harboring a common TP53 missense mutation, R248W.  Relative to 
control and TP53 missense cell lines, we determined that p53 loss leads to increased 
genomic instability which is associated with the presence of supernumerary centrosomes, 
a described mechanism of instability resulting in aneuploidy (80).  Using an unbiased 
proteomic screen, we identified NDRG1 as differentially upregulated in control and TP53 
missense cell lines compared to TP53 null cells, but only under physiological low 
proliferation conditions. We show that forced expression of NDRG1 reduced abnormal 
centrosome numbers in MCF10A and HCT116 p53 null cells, while knock down of 
NDRG1 by RNA interference (RNAi) in TP53 wild type parental cells led to 
supernumerary centrosomes.  Using proximity ligation assays, we found that NDRG1 
associates with γ-tubulin, a key component of centrosomes, thus providing a mechanistic 
link between p53, NDRG1 and centrosome homeostasis. Strikingly, in silico analysis of 
multiple human tumor samples revealed that homozygous loss of TP53 is nearly mutually 
exclusive with NDRG1 overexpression, strongly corroborating our in vitro data to actual 
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human cancers (81, 82).  Taken together, our results provide a new model suggesting that 
under conditions of physiological low proliferation conditions, p53 upregulates NDRG1 
expression, altering its interaction with γ –tubulin, thereby regulating centrosome 
homeostasis in a precise fashion.  In cells with loss of p53, NDRG1 expression is not 
increased during cellular arrest and/or low proliferative states, allowing for 
supernumerary centrosome numbers that results in genomic instability and aneuploidy.   
 
Results 
Distinct phenotypes of p53 null versus p53 R248W heterozygous missense gene 
targeted cell lines.  We have previously described the generation of TP53 null clones in 
the MCF10A cell line using genome editing with recombinant adeno-associated virus 
(rAAV) (83).  MCF10A is a spontaneously immortalized non-tumorigenic human breast 
epithelial cell line (84) that is ideal for genome editing studies given its relatively normal 
karyotype, genome stability and lack of oncogenic mutations (85).  For these studies, we 
utilized two independent p53 null clones: 3b and 4b, hereafter designated KO1 and KO2.  
To characterize phenotypes unique to p53 loss versus common missense mutations, we 
used rAAV genome editing to “knock in” a common TP53 heterozygous missense 
mutation, R248W, using a previously described vector (86) (Fig. 2.1A).  Two 
independently derived clones were isolated and confirmed as having a single site of 
integration and equivalent allelic expression of mutant and wild type alleles (Fig. 2.1B).  
These were designated KI1 and KI2, and used for further studies.   
 MCF10A cells require exogenous growth factors, including epidermal growth 
factor (EGF), for continued proliferation, and indeed, growth factor independence is a 
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hallmark of a transformed phenotype.  Prior work in our lab demonstrated that 
introduction of oncogenic mutations in MCF10A by gene targeting leads to EGF 
independent growth (59).  In addition, our past studies demonstrated that p53 null cells 
could propagate without EGF in 2% charcoal dextran treated serum (83).  However, for 
the current studies, we employed physiological concentrations of EGF (0.2 ng/ml), as we 
have previously shown that this dose of EGF allows for comparison with parental 
MCF10A cells, which are EGF dependent, but can proliferate slowly at this concentration 
(59).  Using physiological doses of EGF also allows for pathway signaling and drug 
sensitivity studies that can be masked by high proliferation rates due to hyperactivation of 
PI3 Kinase and MAP Kinase pathways when using the historic media formulation for 
tissue culture maintenance of 20 ng/ml EGF (59).  
 Under physiological doses of EGF, p53 KO cells proliferated more slowly when 
compared to the MCF10A cells and p53 KI cells (Fig. 2.2A).  Since these cells are 
aneuploid (83), this is consistent with observations that in non-cancerous cells aneuploidy 
can lead to reduced cell proliferation(87).  However, in elevated levels of EGF, p53 KO 
cells demonstrated similar proliferation rates to parental MCF10A cells, consistent with 
our prior report (83) (Fig. 2.2B).  Interestingly, p53 KI cells demonstrated increased 
proliferation in high EGF culture conditions, consistent with studies demonstrating gain 
of function with TP53 missense mutations (30).  In accord with these results, colony 
formation assays also demonstrated no appreciable difference between p53 KO clones 
and parental cells, but p53 KI clones had a significantly increased number of colonies in 
limiting dilution assays (Fig. 2.3).   
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 TP53 is also thought to play a role in preventing genomic instability. Although 
knock out of TP53 by genome editing was not shown to influence chromosomal 
instability (CIN) or lead to aneuploidy in the HCT116 colorectal cancer cell line, p53 null 
HCT116 do have an increased rate of tetraploidy (88), suggesting possible effects of 
genome instability due to p53 loss. In contrast, our past work demonstrated that gene 
targeting of MCF10A cells did lead to aneuploidy, though formal CIN analysis was not 
performed in those studies (83). We therefore performed fluorescent in situ hybridization 
(FISH) with multiple probes and carried out a CIN analysis with our cell line panel.  As 
shown in Figure 2.4, one of two p53 KO cells demonstrated a statistically significant 
elevated rate of CIN compared to parental MCF10A cells and p53 KI cells.  It should be 
noted that KO2 has an increase in chromosomal alterations/aneuploidy relative to KO1 
(83).  Thus it is likely that additional alterations in KO2 account for a high degree of 
CIN, possibly in mitotic spindle check point genes as previously described (89).  In 
agreement with this, using Matrigel and soft agar assays, only p53 KO2 demonstrated 
aberrant acini and colony formation, suggesting this effect was mediated by other 
genomic changes present in this clone (Fig. 2.5). 
 
TP53 loss leads to abnormal centrosome homeostasis and failure to upregulate 
NDRG1 under physiological low proliferation conditions.  Another known mechanism 
of genomic instability is supernumerary centrosomes leading to abnormal chromosomal 
segregation and aneuploidy (80, 90).  To determine whether altered centrosome 
homeostasis was present in p53 null cells, we stained for γ-tubulin as previously 
described(91).  As seen in Figure 2.6, increased centrosomes were seen only in p53 KO 
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cells and not in parental or p53 KI cell lines. This difference was statistically significant 
for both p53 KO clones and suggests a direct effect of p53 loss.  Interestingly, 
supernumerary centrosomes in p53 KO cells were seen predominantly in physiological 
EGF conditions (Fig. 2.6A, B).   However, under high proliferative conditions with 20 
ng/ml EGF, cells displayed increased cytoplasmic fluorescence, which was marked in 
TP53 KO cells (Fig. 2.6C).  Although there did not appear to be an appreciable difference 
in centrosome numbers between parental, TP53 KI and TP53 KO cells in 20 ng/ml EGF, 
accurate quantification could not be determined due to the increased fluorescence 
intensity in TP53 KO cells. 
 In order to gain insight into the mechanism of how p53 loss leads to centrosome 
amplification, we performed reverse phase protein array on protein lysates from our cell 
line panel under physiological EGF conditions.  As seen in Figure 2.7A, one of the most 
notable differences between p53 KO cells and parental and p53 KI cells was the 
decreased expression of phosphorylated NDRG1 and total NDRG1.  NDRG1, also known 
as Drg1, Cap43, Rit42, RTP, and PROXY-1, was first described as differentiation-related 
gene 1 (92, 93).  NDRG1 encodes the 46 kD protein, NDRG1, which is highly conserved 
among multicellular organisms and is ubiquitously expressed in tissues in response to 
cellular stress (94).  Prior studies demonstrated that NDRG1 is necessary but not 
sufficient for p53-mediated apoptosis (95), and may play a role in spindle organization, 
as NDRG1 has been shown to co-localize with centrosomes (96).   However, NDRG1 as 
a direct mediator of p53 regulated centrosome homeostasis has not been demonstrated.  
To correlate and confirm expression of NDRG1 related to abnormal centrosome numbers, 
cells were cultured in physiological and maintenance dosages of EGF, harvested for cell 
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lysates, and used for western blot.  As shown in Figure 2.7B, under conditions of high 
EGF, phosphorylated and total amounts of NDRG1 were not significantly different 
among our panel of cell lines.  However, under physiological doses of EGF and lower 
proliferation rates, parental MCF10A cells and p53 KI cell lines displayed a dramatic 
increase in NDRG1 expression by western blot (Fig. 2.7B).  In contrast, p53 KO cell 
lines demonstrated minimal to no increase in NDRG1 protein.  These data suggest that 
p53 directly regulates expression of NDRG1 that is governed by the proliferative state of 
the cell.  Of note, phosphorylated NDRG1 and total NDRG1 levels were consistently 
similar for all experiments, suggesting that differential phosphorylation of NDRG1 was 
not involved with any functional role between p53 KO and parental cell lines, and that 
p53 may be directly regulating gene expression of NDRG1. 
 
p53 increases under physiological low proliferative conditions and binds the promoter 
region of NDRG1. We initially tested whether lowering cell proliferation to 
physiological levels would have the expected result of increasing p53 protein levels in 
MCF10A cells. As shown in Figure 2.8A, both MCF10A and p53 KI cells demonstrated 
relative increases in p53 when placed in physiological EGF conditions, though was 
absent as expected in p53 KO cells. It should be noted that the p53 KI cells showed 
elevated levels of p53, consistent with this missense mutation’s ability to stabilize the p53 
protein (43).  Using the same antibody, we next performed ChIP to determine if p53 was 
bound to a consensus p53 binding site within the NDRG1 promoter and whether this 
binding increased in physiological EGF conditions.  Quantitative real time PCR 
demonstrated that parental cells had significantly increased binding of p53 at the NDRG1 
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promoter under physiological EGF conditions relative to high EGF conditions.   As 
expected, no binding of p53 was observed in the p53 KO cells regardless of EGF 
conditions (Fig. 2.8B).  Interestingly, p53 KI cells had a relatively low increase in p53 
binding, perhaps indicating that expression of wild type p53 from the unmodified allele 
could still mediate some binding at the NDRG1 promoter despite the presence of the 
dominant negative R248W allele.  Together, these data strongly support that NDRG1 is a 
p53 inducible gene. 
 
Homozygous deletion of TP53 is mutually exclusive with NDRG1 overexpression in 
human cancers.  To further substantiate the link between p53 and NDRG1, we reasoned 
that human cancers with homozygous deletion of TP53 would be unable to upregulate 
NDRG1 gene expression.  The cBioPortal database provides gene expression, mutational 
status, and protein expression from a number of clinical studies including from The 
Cancer Genome Atlas (TCGA)(81).  Using this database, we analyzed a potential inverse 
relationship between homozygous loss of TP53 and NDRG1 overexpression across a 
variety of cancers.  To distinguish any differences between TP53 homozygous deletion 
and TP53 missense mutations, only cancer sets containing both TP53 homozygous 
deletion and mutations were investigated.  Within cBioPortal, twenty-four datasets 
contained genomic information on cancers with TP53 homozygous deletions, TP53 
missense mutations, and NDRG1 overexpression, representing thousands of patients.  
When analyzing tumors with TP53 alterations (n=3132), (Fig. 2.9, SI Fig. 1), 
homozygous deletion of TP53 was found in 153 cases with only 6 demonstrating NDRG1 
overexpression (3.9%).  In contrast, 2979 cases were found to have TP53 missense 
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mutations, of which 387 demonstrated NDRG1 overexpression (14.0%).  This result was 
highly statistically significant by Chi square test (p < 0.000957) (SI Fig. 1C).  These data 
strongly suggest that homozygous loss of TP53 prevents overexpression of NDRG1, but 
this is not seen with common TP53 missense mutations.  These results support that our in 
vitro studies are directly relevant to a large and diverse population of human cancers. 
 
NDRG1 affects centrosome homeostasis. Having established that NDRG1 is a p53 
inducible gene, and the applicability of this relationship to human cancers, we next 
sought to determine if NDRG1 directly affected centrosome homeostasis.  We first 
generated NDRG1 knock down clones with short hairpin RNAi (shRNA) vectors in the 
parental MCF10A cell line. As seen in Figure 2.10, shRNA against NDRG1 led to a 
significant decrease in protein levels in both physiological and high EGF conditions.  In 
addition, we established NDRG1 overexpressing cell lines in p53 KO cells via 
transfection of a full length cDNA.  As shown in Figure 2.10B, NDRG1 p53 KO 
overexpressing cells had high levels of NDRG1 in physiological EGF conditions.  These 
cell lines were then subjected to centrosome analyses.  As shown in Figure 2.11, knock 
down of NDRG1 in parental p53 wild type cells demonstrated an increase in centrosomes, 
while NDRG1 overexpression in p53 KO cells resulted in a statistically significant 
decrease in centrosome numbers.  To determine if these results were generally applicable, 
we repeated these studies using a very different cell line, HCT116. This is a human 
colorectal cancer cell line with a microsatellite instability phenotype, and p53 KO cells 
have been previously described (97).  We generated NDRG1 knock down cells with 
shRNA in parental p53 wild type HCT116 cells, as well as NDRG1 overexpressing cells 
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in HCT116 p53 KO cells akin to our MCF10A cell line panel and verified protein 
expression by western blot (Fig. 2.12A).  As demonstrated in Figure 2.12B and C, knock 
down of NDRG1 in HCT116 parental cells led to a modest but significant increase in 
centrosome number, while overexpression of NDRG1 in HCT116 p53 KO cells led to a 
dramatic decrease in centrosome amplification compared to p53 KO cells.  These data 
confirm our results in MCF10A cells, and demonstrate that the level of NDRG1 directly 
regulates centrosome homeostasis. 
 
NDRG1 interacts with γ –tubulin, a major component of the centrosome.  A potential 
interaction between NDRG1 and γ-tubulin has been previously reported as both proteins 
are present within the same fraction in co-sedimentation assays (98).  In order to confirm 
that NDRG1 directly interacts with centrosome assembly and mitotic division in vitro, a 
proximity ligation assay (PLA) was carried out with antibodies against NDRG1 and γ-
tubulin.  PLA relies upon antibody detection of proteins and if the antibodies are within 
40 nm of one another, then ligation of PLA probes occurs followed by amplification and 
fluorescence probe detection in situ.  As shown in Figure 2.13, MCF10A, p53 KI and p53 
KO demonstrated positive signals relative to the provided negative controls in 
physiological EGF conditions.  However, signals were reduced in intensity and number in 
p53 KO cells. Interestingly, numerous positive fluorescence signals were identified 
throughout the cells, suggesting that NDRG1 and γ-tubulin are continuously associated 
throughout the cell cycle and are not limited to the centrosomes. These results suggests 
that NDRG1 and γ-tubulin physically interact throughout the cell cycle, and therefore 





TP53 is the most altered tumor suppressor gene in all human cancers. It is clear 
after decades of research that p53 has many roles in both normal and cancer cells, and 
that common missense mutations have distinct functional consequences compared to 
complete loss of p53, though both are found in human cancers.  Despite numerous 
studies, there remain areas of uncertainty as to p53’s role as the “guardian of the genome” 
in maintaining genomic stability.  Using a panel of isogenic cell lines, our study provides 
new mechanistic insights into how p53 regulates the centrosome via NDRG1 depending 
on the proliferative status of the cell, and helps reconcile past conflicting studies 
regarding p53, centrosome homeostasis and aneuploidy. 
 Conflicting studies on whether loss of p53 function leads to aneuploidy and/or 
CIN likely are due to differences in cell lines and models used to study these phenotypes 
(83, 88).  Furthermore, as demonstrated here, p53 missense mutations have a profoundly 
different effect than homozygous deletion on a variety of cellular functions and past 
studies have varied in the methods used to inactivate p53.  In addition, prior work using 
p53 null mouse embryonic fibroblasts suggested that p53 does indeed directly regulate 
centrosome homeostasis and subsequently aneuploidy(99), while other reports refute this 
notion(100).  We propose that p53 does not directly alter CIN, as missense mutations did 
not have appreciable increase in CIN.  Further, we speculate that loss of p53 does not 
directly affect CIN as only one of two p53 KO clones, KO2, demonstrated significantly 
elevated CIN and an increased aneuploid karyotype (83), suggesting that CIN in this 
clone resulted from secondary genetic events.  Consistent with this notion, HCT116 p53 
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KO cells also do not display CIN, though they do tend to become tetraploid(88).  
However, our data provide a model whereby loss of p53, but not mutation, leads to 
abnormal centrosome amplification with resultant aneuploidy, specifically during low, 
yet physiologically relevant levels of proliferation.  As most cell lines in culture are in a 
highly proliferative state, including HCT116, centrosome amplification and aneuploidy 
may or may not be seen depending on the proliferative index and status of NDRG1 
protein levels, as demonstrated in this study.  The ability to precisely control MCF10A 
proliferation using varying doses of EGF allowed us to identify this property in p53 null 
cells.  Moreover, the striking inverse correlation between homozygous loss of TP53 and 
overexpression of NDRG1 using the cBioPortal database, strongly supports that our 
model is applicable to human cancers. Although it is arguable that cancers are hallmarked 
by a high proliferation index, perhaps questioning our model’s relevance, many human 
cancers are in fact known to have a low proliferation rate, particularly in early stage 
disease.  For example, the majority of oestrogen receptor positive breast cancers display 
very low rates of proliferation as measured by Ki-67 staining.  In addition, since loss of 
p53 is an early event in some tissue types with low proliferation rates, our model provides 
an explanation as to how loss of p53 under conditions of low cell proliferation could 
provide the necessary genomic instability that results in subsequent alterations and 
ultimately leads toward a more aggressive cancer phenotype. 
 This work also provides a new mechanistic link between p53, NDRG1, 
centrosome homeostasis and maintaining genome stability (Fig. 2.14).  We propose that 
loss of p53 is more than a “permissive” event that allows cells with damaged DNA to 
continue through the cell cycle leading to mutations and aneuploidy.  Instead our data 
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suggests that loss of p53 in cells that are undergoing low proliferation fail to upregulate 
NDRG1, a p53 inducible gene.  In turn, this inability to increase NDRG1 expression 
dysregulates normal centrosome homeostasis, resulting in supernumerary centrosomes 
with resultant aneuploidy.  Although we show that NDRG1 interacts with γ-tubulin, a 
principal component of the centrosome, we do not yet know how lower levels of NDRG1 
during low proliferative states affects centrosome homeostasis. However, it is tempting to 
speculate that NDRG1 normally sequesters γ-tubulin under low proliferative states such 
that only the proper amount is available for a normal number of centrosomes to be 
synthesized.  In the absence of p53, NDRG1 is not appropriately increased, leading to 
excess γ-tubulin and increased numbers of centrosomes with resultant aneuploidy. This 
model is supported by our PLA results examining the association of NDRG1 and γ-
tubulin in p53 KO versus parental and p53 KI cell lines. 
 In conclusion, we have identified that loss of p53 leads to a distinct form of 
genomic instability mediated by abnormal centrosome numbers, specifically under 
conditions of low cell proliferation.  These results have potential translational 
implications as cancers with complete loss of p53 may have a form of genomic instability 
that may be “turned off” by paradoxically administering mitogens that induce a higher 
rate of proliferation.  As genomic instability is thought to be the driver of clonal evolution 
and drug resistance, this provocative strategy could potentially allow for use of cytotoxic 
therapies that are currently thought to be less effective for cancers with a low 
































































Putative p53 binding site 
FWD 5’-AAGTGAAGGGAGTCGCTCAG 
REV 5’-GTTGCGCAAGCAGTCGTAG 
Negative control: Upstream    













































































As mentioned in Chapter 1, each year approximately 11,000 new cases of breast 
cancer will harbor both a TP53 and PIK3CA mutation.  TP53 and PIK3CA are the two 
most frequently mutated genes in primary breast cancer and have the highest rate of co-
occurrence among the top five mutated genes in breast cancer (75).  While most clinical 
samples consist of primary tumors, TP53 is often associated with late stage cancer 
progression and metastasis. This suggests there is a higher co-occurrence of TP53 and 
PIK3CA in metastatic disease than the co-occurrence that is presented in primary tumors.  
The studying of PIK3CA and TP53 in the context of one another will provide invaluable 
insight into how genetic mutations cooperate to develop breast cancer.   
It has previously been shown that the p53 and PI3K pathways intersect and 
interact at several points.  In the early 2000s, a number of studies revealed several points 
of interaction between p53 and PTEN (phosphatase and tension homolog).  PTEN’s 
primary function is a lipid phosphatase that works to reverse the phosphorylation reaction 
catalyzed by PI3K.  The first point of interaction was identified by Stambolic et al. in 
which they showed a functional p53 binding site within the PTEN promoter (101).  This 
interaction suggests that p53 is capable of directly regulating PTEN expression within the 
PI3K pathway.  A second point of interaction was identified at the Mdm2 point on the 
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p53 pathway and showed that PTEN was able to negatively regulate Mdm2 through its 
P1 promoter.  This implies that PTEN was capable of preventing the degradation of p53 
by suppressing the AKT pathway (102, 103).  Soon after, a third point of interaction was 
suggested by Freeman et al. which demonstrated a physical association between p53 and 
PTEN proteins, preventing the degradation of p53 (104).  In 2002, Singh et al. suggested 
the two pathways interacted at the transcriptional level and provided evidence that p53 
negatively regulates PIK3CA transcript and protein levels (105).  This observation was 
reconfirmed in 2007 when Kim et al demonstrated that the activation of PI3K signaling 
by mutations in PIK3CA can lead to the activation of p53-mediated growth suppression 
in human cells.  These studies suggested that functional p53 provides a brake on 
phosphatidylinositol (3,4,5)-triphosphate-induced mitogensis during human 
carcinogenesis (106).  This was confirmed by a study suggesting that PIK3CA is 
regulated by p53 at an alternative promoter site.  Furthermore, the study suggests that the 
loss of p53 function may be one of the mechanisms that contributes to the increased 
p110α levels in ovarian and other cancers (107). 
In 2011, a group of scientists suggested that in the absence of DNA damage the 
activated AKT pathway induces senescence in human cells via mTORC1 and p53.  
Through shRNA-mediated knockdown of p53, Astle et al identified p53 as an important 
potential barrier to PI3K/AKT-driven tumorigenesis (108).  In the same year, Adams et al 
used a mouse model to imply that PIK3CA and TP53 mutations cooperate in mouse 
mammary tumor formation.  Using a MMTV-Cre system, Adams showed that 
cooperation between the PIK3CA H1047R mutation and a p53 loss-of-function mutation 
was not on the level of proliferation or apoptosis, the two gene’s respective pathways.  
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Furthermore, the study showed that mutations within the two genes lead to mammary-
specific tumor formation with poor differentiation and an increased aggressive phenotype 
(109).  This implied that the two genes interacted synergistically in breast carcinogenesis.  
All these studies suggest that the accumulation of both a PIK3CA and TP53 mutation 
play a combined and important role in breast tumor development.   
However, despite evidence and a heavy focus on the interplay of oncogene and 
tumor suppressor genes, two important caveats of current models must be addressed.  
First, most studies are performed in murine, not human, cells and therefore are not 
completely representative of human cancers.  Second, most human studies utilize ectopic 
overexpression of oncogenes, which is not representative of biologically expression in 
cancers, and could lead to the artificial activation of p53 and other important pathways 
(106, 110).  This study addresses these issues through the development of a panel of 
human cell lines within a relatively isogenic background in a biologically relevant 
setting.  Furthermore, the panel of cell lines provides an accurate representation of tumor 
heterogeneity and may provide a platform for understanding and overcoming this 
problem in a clinical setting. 
Cancer is a highly complex and multifaceted disease with varying acquired 
capabilities, hallmarks, and phenotypes due to both inter- and intratumroral 
heterogeneity.  This inherent functional variability is due to both genetic and non-genetic 
processes.  Genetic variations among tumors are the result of genomic instability, 
secondary mutations, and clonal variation and selection.  However, tumor heterogeneity 
in the absence of genetic differences remains incompletely understood.  Mechanisms of 
nongenetic tumor heterogeneity consist of, but are not limited to, bidirectional interaction 
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between tumor cells and microenvironment, the inter-convertible activation of GTPases, 
metastable configurations of intracellular networks, and altered epigenetic states (111).  
The most prominent genetic mechanism of heterogeneity is genomic instability which 
generates a pool of somatic mutations that can result in the potential selection given 
microenvironment context and development of varying hallmark capabilities (112).  In 
this study we demonstrate that the incorporation of both a TP53 and PIK3CA mutation 
into a panel of closely related cell lines results in the development of genomic instability 
in a controlled, relatively stable background. The panel also provides an invaluable tool 
in comparing and attributing phenotypic differences to primary and/or acquired 
secondary mutations.   
A panel of isogenic cell lines harboring both a TP53 and PIK3CA mutation will 
provide a biologically relevant model to investigate the proposed synergistic relationship 
between the two mutations.  Furthermore, the panel will provide an environment in which 
the mutations are expressed at physiological levels within a controlled background.  
Through the incorporation of these mutations and the onset of genomic instability in a 
stable cell line provides an important tool in understanding how different mutated 
pathways behave in cancer.  Furthermore, the inherent tumor heterogeneity observed 
between clones within the panel provides a model for associated primary and secondary 
mutations to observed phenotypes.    Understanding how multiple pathogenic mutations 
and pathways interact and the ability to take advantage of these alterations will provide 
the basis and rationale for future targeted therapies and a better understanding of breast 





Cells harboring both a PIK3CA and TP53 mutation exhibit a distinct growth 
advantage. In order to study TP53 and PIK3CA mutations in the context of one another, 
an isogenic panel of cell lines harboring both a PIK3CA mutation and TP53 mutation was 
developed using genome editing with recombinant adeno-associated virus (rAAV) (83).   
A schematic representation of the panel is shown in Figure 3.1.   Two vectors previously 
developed in the lab were utilized to knock in the oncogenic hotspot PIK3CA mutations, 
E545K and H1047R into MCF10A cells already containing either the TP53 R248W 
mutation or a homozygous deletion (Fig. 3.2) (59, 113).  Sanger sequencing was used to 
confirm the incorporation of both the PIK3CA and TP53 mutation in their respective 
genes, a 50:50 biallelic ratio, and cDNA expression (Fig 3.3-3.6).  Clones for each set of 
mutations were developed separately using independently derived parental clones.   
To assess growth phenotype, proliferation assays were carried out in 6 well plates 
in the absence of EGF.  As previously mentioned, parental MCF10As require the 
presence of EGF to maintain normal growth and avoid growth arrest.  It was previously 
shown by the lab that incorporation of a PIK3CA hotspot mutation lead to EGF-
independent growth (59).  In the absence of EGF, all cell lines harboring a PIK3CA 
mutation exhibited increased growth (Fig 3.7A).  Furthermore, cell lines harboring both 
the R248W hotspot mutation and a PIK3CA mutation showed a significant growth 
advantage (***p<.001) to the TP53 KO/PIK3CA counterpart.  In physiological doses of 
EGF, initially the double mutant cell lines experienced similar growth to the parental cell 
lines.  However, as the parental and single mutant cells become confluent they experience 
cell-cell contact inhibition to suppress further cell proliferation.  Conversely, cells 
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harboring two mutations exhibited continued proliferation after reaching confluency (Fig. 
3.7B.   The loss of contact inhibition is a transformative property often leading to the 
development of cancer (6).  The loss of contact inhibition in cell lines harboring both 
mutations suggests that PIK3CA and TP53 cooperate in cancer-like properties.  To 
investigate this synergistic relationship between PIK3CA and TP53, other transformative 
properties were further investigated. 
 
Double mutant cell lines exhibit morphological changes and anchorage-independent 
growth in 3D culture.  The panel of isogenic double mutant cell lines and parental cell 
lines were cultured in Matrigel, a three-dimensional basement membrane culture which 
supports acini formation of mammary epithelial cells in vitro.  Matrigel provides a culture 
environment similar to the natural interstitial space and provides a better medium for 
observing morphological changes.  Normal morphology is a round acinar with well-
defined borders and central clearing for the formation of the lumen.  It has been 
previously shown that the parental MCF10As and single mutant cell lines form regular 
acini in physiological doses of EGF (59).  Cell lines harboring both a TP53 and PIK3CA 
mutation showed significant morphological changes, including protrusions at the borders 
of acini, bridging between neighboring acini, and loss of structural integrity (Fig. 3.8).  It 
was previously shown that these features resembled the invasive process of cancers and 
are often seen in cells with increased MAP Kinase and PI3 Kinase activation as a result 
of high supplemental doses of EGF (114).  The observed phenotype for the double 
mutant cell lines suggests an increase in MAP Kinase activation and cooperation of TP53 
and PIK3CA in breast carcinogenesis.  
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 In order to assess the double mutant panel’s capacity for anchorage-independent 
growth and invasive capabilities, cells were grown in a semi-solid soft agar.  Growth in 
soft agar allows for early microscopic examination of transformation, and allows for the 
observation of morphological changes.  A liquid layer of media on top of the semi-solid 
medium allows for the replenishment of nutrients at frequent intervals.    As with the 
Matrigel acini formation assay, all cells were cultured in physiological doses of EGF. In 
agreement with previously published studies, parental and single mutant cells did not 
exhibit transformative or invasive properties.  However, the double mutant cell lines were 
capable of extensive colony formation (Fig. 3.9).  This confirmed that the double mutant 
cell lines, in physiological doses of EGF, exhibit transformative properties that cause an 
increased capacity for anchorage independent growth and invasive capabilities.  
 
Double mutant cell lines show increased AKT phosphorylation and pathway activation.  
In order to determine if the increased transformative properties observed in the three 
dimensional tissue culture was due to PIK3CA-TP53 cooperative activation, the AKT and 
ERK pathways were examined using western blot analysis. It was previously shown that 
the incorporation of a PIK3CA mutation into MCF10A led to increased phosphorylation 
and therefore, activation, of the AKT pathway (59).  Using RPPA and western blot 
analysis it was observed that in the absence of EGF, cell lines harboring both a PIK3CA 
and TP53 mutation showed increased AKT phosphorylation when compared to both the 
single mutant cell lines and parental MCF10A (Fig 10A). This suggests that mutations 
within the PIK3CA and TP53 gene show a synergistic relationship within the AKT 
pathway.  All double mutant cell lines showed increased phosphorylation within the AKT 
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pathway when compared to the single PIK3CA mutant cell lines.  Similarly, the double 
mutant cell lines showed elevated phosphorylation of ERK and p90RSK in the absence of 
EGF when compared to both the parental and single mutant cell lines (Fig. 3.10B).  It 
was previously demonstrated that in the absence of EGF, single PIK3CA mutations were 
not sufficient for mTOR activation but showed a reduced activation threshold in low 
levels of EGF.  However, unlike the single mutant PIK3CA KIs, in the absence of EGF 
the double mutant cell lines showed varying levels of phosphorylation of p70RSK (Fig. 
3.10B). This suggests that mutations in both TP53 and PIK3CA are required to 
accomplish complete mTOR activation. 
 
Double mutant cell lines exhibit a higher rate of centrosome amplification and 
genomic instability which may lead to increased copy number variation (CNV).  As 
previously mentioned in Chapter 2, another known mechanism of genomic instability is 
supernumerary centrosome numbers leading to abnormal chromosomal segregation and 
aneuploidy (24, 115).  To determine whether altered centrosome homeostasis was present 
in the double mutant panel of cell lines, we stained for γ-tubulin as previously described 
in Chapter 2.   In physiological EGF conditions, it was observed that all double mutant 
cell lines experienced a significant (* p<.05) increase in centrosome amplification when 
compared to the parental and single mutant cell lines (Fig. 3.11A).  Additionally, cell 
lines harboring both a mutation in PIK3CA and TP53 exhibited irregular mitotic bodies 
due to centrosome amplification (Fig. 3.11B).  This has been shown to lead to 
chromosomal misseggregation and aneuploidy, and is an underlying contributor to loss of 
cell cycle fidelity, genomic instability, and loss of tissue structure in human cancers 
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(116).  In order to determine if double mutants experienced a higher rate of genomic 
instability, Fluoresence In Situ Hybridization (FISH) was performed on the panel of cell 
lines.  FISH provides information for changes in both the genomic state, aneuploidy, and 
the genomic rate, change from the modal population.  Double mutants showed varying 
degrees of increased genomic instability when compared to the parental, single mutant 
cell lines (Fig. 3.12).  The variability may be due to the randomized selection of a limited 
number of genes.  The successful incorporation of genomic instability into a panel of cell 
lines with a relatively isogenic background provides a novel and invaluable resource for 
understanding and exploiting characteristics of cancer for individualized therapy.  
Furthermore, the variability observed among the panel suggests that any observed CIN 
would be an indirect effect of the mutation of the two pathways.  Through additional 
analysis, the identification of clone specific modifications and secondary mutations could 
potentially be attributed to variations in phenotypes and provide a better understanding of 
carcinogenesis.   
Preliminary genomic analysis was carried out using Illumina’s OmniExpress 
ChIP Array in order to do a genome wide SNP and CNV analysis within the panel.  
Within the double mutant panel, cell lines harboring both a PIK3CA and a TP53 mutation 
showed a higher number of genomic alterations (Fig. 3.13).  Although some genomic 
alterations were shared among the different clones, varying degrees of loss and gain 
suggest that in the presence of two mutations there is a considerable increase in genomic 
instability leading to changes in SNP and CNV.  Furthermore, as expected based on 
chapter 2’s studies, cell lines with a TP53 homozygous deletion exhibited the highest 
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level of CNV.  This coincides with the increased levels of genomic instability observed in 
Figure 3.12. 
 
Double mutant cell lines show an increase in cell cycle progression and aneuploidy.  In 
order to determine if the loss of PIK3CA and TP53 lead to an increase in cell cycle 
progression, the panel of cell lines was analyzed using propidium iodide and flow 
cytometry.  In both the absence and low doses of EGF, the double mutants showed a 
significantly (** p<.01) higher population of cells in S and G2/M phase (SI Fig. 3A).  It 
can be theorized that this is due to the loss of the critical p53 cell checkpoint and the 
increase in proliferation due to the PIK3CA mutation.  Often the loss of p53 has been 
found to lead to a G2/M cell cycle arrest, regardless of external growth factors (24).  
Furthermore, it was observed that the KO_9 experienced a higher population of G2/M 
phase.  This is attributed to the clonal variation and tumor heterogeneity.  The loss of p53 
leads to the accumulation of many other mutations which in turn can be cause for 
variations observed between clonal cell lines.   As with the TP53 single mutant cell lines, 
the ploidic state of the cell line was also observed using flow cytometry.  It was found 
that the double mutant panel, as a whole, exhibited a higher percent population of cells 
exhibiting > 4n, in both the absence and low doses of EGF (SI Fig. 3B).  Similar to the 
cell cycle analysis, when individual cell lines were analyzed, the KO_9 cell line exhibited 
almost a 10-fold higher percentage of polyploidal cells (Fig 3.10B).  This was again 






Since the discovery of TP53 and PIK3CA mutations in human cancer, ample data 
has been accumulated describing their involvement in tumorigenesis and demonstrating 
the dysregulation of these two pathways in cancer.  However, studies have only recently 
begun to focus on the interaction of these two mutated pathways together in cancer.  
Using a panel of isogenic cell lines harboring both a PIK3CA and TP53 mutation in a 
nontumorgenic breast epithelial background, our study provides a better understanding 
for mutational cooperation in breast carcinogenesis and furthermore, helps to elucidate on 
tumor heterogeneity.  The ability to understand the molecular and phenotypic differences 
within cancer subtypes is critical for understanding and overcoming disease 
heterogeneity.   
With only rare exceptions, all spontaneous tumors theoretically originate from a 
single cell, yet the majority of human tumors display a high degree of heterogeneity in 
many morphological and physiological features (117).  Due to substantial technical 
challenges, definitive publications on clonal heterogeneity are scarce.  This study 
provides a platform for understanding clonal differences between a set of closely related 
cell lines harboring the two most common mutations in breast cancer.  As demonstrated 
by our study, certain phenotypic transformations were the cooperative result of the 
dysregulation of PIK3CA and TP53.  In both the absence and physiological doses of 
EGF, the double mutants demonstrated a significant growth advantage.   In physiological 
doses of EGF, the double mutants did not experience cell-cell contact inhibition 
suggesting the potential for uncontrolled growth, a main characteristic of cancer.  
Additionally, irregular acini formation and invasive growth in 3D culture were observed 
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only in the presence of mutations in both TP53 and PIK3CA, regardless of the type of 
mutation.  Similar transformative properties are not observed in the parental MCF10A or 
single mutant clones.  The absence of these transformations in the single mutant cell lines 
suggests that mutations in both pathways are required to observe transformative 
properties in 3D culture.  This suggests that these observed transformations are the 
synergistic result of dysregulation of the two pathways.  While the dysregulation of both 
the TP53 and PIK3CA pathway was enough to confer increased proliferation and 
irregular growth in 3D culture, it was not sufficient for tumor development in vivo.  
Therefore we can infer that the acquisition of these two mutations may be critical but not 
sufficient for tumorgenesis. 
Conversely, when looking at certain molecular changes, such as phosphorylation 
within the AKT and ERK pathway, there was significant clonal variation within the 
panel.  It was previously shown that mutations within the PIKCA gene lead to elevated 
levels of AKT phosphorylation in the absence of EGF, as well as a reduced threshold for 
ERK pathway phosphorylation in low EGF conditions (59). Cells harboring a mutation in 
both PIK3CA and TP53 showed varying degrees of elevated phosphorylation in the 
absence of EGF when compared to the single mutant counterparts.  It was concluded that 
mutations in TP53 and PIK3CA lead to cooperated dysregulation of the AKT and ERK 
pathways but the varying degrees of phosphorylation were due to secondary mutations 
resulting from genomic instability.  Genomic instability was confirmed in the double 
mutants using fluorescent in situ hybridization (FISH).   Genomic instability has been 
implicated as a common result of p53 alterations, regardless of type, however, no 
systematic analysis of several p53 mutant clones has not been conducted (118, 119).  Our 
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studies show that while genomic instability was the direct result of the two mutations, 
CIN was not.  The significant level of variability suggests that observations of CIN would 
be the result of secondary mutations and not the direct result of alterations in TP53 and 
PIK3CA.  Furthermore it was observed that there was significant variability in the 
genomic stability among the different p53 clones.   This proposes that tumor 
heterogeneity and secondary, acquired mutations, play a significant role in the 
development of genomic instability as a result, p53 mutants have significant variability. 
The successful incorporation of genomic instability into a panel of related cell lines more 
accurately mimics the clinical manifestations of a tumor and allows observed 
transformative properties to be conclusively associated with either primary mutations, 
which were intentionally incorporated, or secondary mutations, which were acquired 
through genomic instability.   
A noteworthy contribution of the panel is that it provides a solution to a 
significant flaw in previously models, which focused on a single clonal population.  By 
providing two separately derived clones with the same set of mutations, and furthermore, 
looking at two different mutations per gene, we gain the ability to attribute observed 
transformative phenotypes to the dysregulation of both genes or a single, a specific 
mutation, a clonal subset of the population, or any potential combination.  Furthermore, 
due to relatively isogenic nature of MCF10A derivatives, clones expressing unique 
transformative properties can be compared to their sister cell line, which contains the 
same primary mutations.  SNP and CNV variations observed within the varying clone 
could potentially be linked to the observed unique transformative property and provide a 
stronger understanding for how cancer develops. 
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The panel demonstrates and provides a strong model for observing and 
understanding tumor heterogeneity and resulting phenotypic differences.  The 
development of a panel of independently derived mutations in the same parental 
background provides a relatively controlled model for observing clonal variation.  A 
significant obstacle in tumor resistance is tumor heterogeneity and acquisition of 
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Clinical Applications of the Double Mutant Panel 
Introduction  
Drug resistance is a significant obstacle in cancer treatment and severely limits 
the effectiveness of chemotherapies.  In 2005, 90% of treatment failure in patients with 
metastatic cancer was attributed to both intrinsic and acquired drug resistance (120).   
Often times, acquired resistance to one chemotherapy has also been shown to lead to 
cross-resistance to other drugs with different mechanisms of action.  The ability to further 
understand the molecular mechanisms of drug resistance and to characterize pathways 
involved in regulating tumor cell response to therapy will significantly aid in the 
development of new targeted therapies.   Furthermore, the ability to develop a regime of 
combined chemotherapies utilizing both new targeted therapies and cytotoxic drugs to 
enhance chemotherapy activity will provide increased success in battling drug resistance.  
This study proposes the utilization of a double mutant panel to identify effective regimes 
based on a cell’s genetic composition.  A panel of closely related cell lines harboring 
variations of the two most commonly mutated genes in breast cancer may provide new 
insight for both novel and current chemotherapies. 
In recent years the rise of genome-scale gene expression profiling and continued 
advances in genetics and genomics have revealed new genes and pathways that are 
somatically altered and coexist in human cancers.  These technologies have been used to 
emphasize that mechanisms of carcinogenesis rely on the interaction of 
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genes/proteins/molecules rather than individual mutations (121).  As previously 
mentioned, Di Nicolantonio and colleagues demonstrated that PIK3CA mutations, while 
sensitive to rapamycin individually, became resistant in the presence KRAS or BRAF 
mutations demonstrating the importance of studying molecular markers in the context of 
one another (76, 122).  Therefore, it is becoming increasingly apparent that the successful 
understanding and treatment of breast cancer will rely on understanding multiple targets 
and utilizing combined therapies.  
While combination therapies and the targeting of multiple biomarkers will 
increase the effectiveness of current and new chemotherapeutics, a continued obstacle in 
the effective treatment of cancer is genomic instability and continued tumor 
heterogeneity.  Often, genetically unstable tumor cells can harbor pre-existing primary 
mutations or acquire secondary mutations which lead to the development of drug-
resistance.   The successful incorporation of genomic instability and the resulting tumor 
heterogeneity into a panel of closely related cell lines allows for the understanding and 
identification of effective targeted therapeutics across a clonally diverse population.  In 
addition to understanding and combating mechanisms of drug resistance, it is imperative 
to increase the ability to better predict therapy response.  Currently, no valid practical 
biomarkers exist for many commonly used cytotoxic drugs, including but not limited to 
doxorubicin, paclitaxel, and docetaxel.  In this study we demonstrate through an 
extensive panel of relatively isogenic cell lines, that in the presence of a PIK3CA 
mutation, regardless of TP53’s mutational status, cell lines have an increased sensitivity 
to Paclitaxel.  The identification of multiple biomarkers would provide the opportunity 
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for individualized combination therapies that would potentially lead to an increase in 
successful treatment of cancer.   
The characterization and potential variations in drug response of the proposed 
PIK3CA-TP53 double mutant model may provide essential insight in the mechanism of 
common chemotherapeutic drug resistance.  Recently, it has been demonstrated that 
combination therapies that target multiple molecular markers offer a highly specific 
method for eradicating cancer and may provide an effective strategy for eliminating 
potential drug resistance (123).  Targeting PIK3CA and TP53 hotspot mutations in a 
single model provides better insight on drug effects in the context of multiple mutations 
and offer a more accurate molecular model for treating cancer.  The successful 
incorporation of genomic instability and modeling of tumor heterogeneity provides a 
biologically relevant platform for modeling cancer in vitro and providing a platform for 
the development and testing of personalized therapy.  Furthermore it may provide the 
basis for the development of multi-biomarker systems. 
 
Results 
Double mutant cells show drug-specific susceptibility and resistance when compared to 
single mutation and parental cell lines.  In order to determine the appropriate drug 
concentrations specific for the panel of cells in the specified conditions (see Materials 
and Methods), IC50 curves were performed for each drug (Fig 4.1).  Concentrations 
which indicated potential selective toxicity were selected and pharmacokinetic studies 
were performed.  A table of the drugs involved in this study are listed in Table 4.1.  
Initially, pharmacokinetic studies in which the double mutants experienced an obvious 
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decrease or increase in viability were examined and two drugs were identified.  The first 
drug, MK2206, is an AKT inhibitor which binds to and inhibits AKT in a non-ATP 
competitive manner (124).  The expected result is a decrease in PI3K/AKT signaling and 
the induction of cell apoptosis.  The panel of cell lines was exposed to 1.5 µM for 1 week 
in 6 well plates.  Parental MCF10As and cell lines harboring only a TP53 mutation 
experienced insignificant changes in growth.  However, as predicted, cell lines harboring 
a PIK3CA mutation experienced a marginally significant (*p<.05) decrease in viability 
(Fig 4.2).  Additionally, cell lines harboring both a PIK3CA and TP53 mutation exhibited 
a slightly larger decrease in viability.  The increased susceptibility of cells harboring both 
a PIK3CA and TP53 mutation suggests that MK2206 may be the ideal drug for tumors 
harboring both these mutations and that the mTOR activation in the absence of EGF 
previously shown suggests that these two pathways may be exploited for increased 
specificity and toxicity.   
The second drug with an observable difference between cell sets was Lapatinib.  
Lapatinib is an EGFR/Her2 inhibitor that reversibly blocks phosphorylation of the 
epidermal growth factor (EGFR), ErbB2, Erk-1/2, and AKT kinases (124).  As with 
MK2206, the expected result is a decrease in phosphorylation and activity of the AKT 
pathway in cells harboring a PIK3CA mutation.  The panel of cell lines was exposed to 
.26 µM for 1 week in 6 well plates.   However, unlike MK2206, there was a significant 
increase (*p<.05) in resistance in cells harboring both a PIK3CA Ex. 20 and TP53 
mutation (Fig 4.3).  The same resistance was not observed for cells harboring a PIK3CA 
Ex. 9 mutation.  Similar to Nicolantonio et al’s findings, the Lapatinib pharmacokinetic 
study provides another example of how cells react to drugs very differently depending on 
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the presence or absence of certain mutations and may help to provide a stronger 
understanding to drug resistance.  
 
Double mutant cells exhibit drug-specific tumor heterogeneity.  Within the double 
mutant panel, many drugs did not perform as expected.  PRIMA-1 (p53-Reactivation and 
Induction of Massive Apoptosis), is a small molecule that was previously shown to 
restore p53 function in cells harboring mutant p53 (125).  The panel was exposed to 6 
µM for 1 week in 6 well plates.  There was no observable difference between the parental 
MCF10A, TP53 KOs and TP53 R248W KIs (Fig. 4.4).  However, when TP53 KI 
mutations were in the presence of a second, PIK3CA there was a marginal but observable 
decrease in cell viability (indicated by the red arrows).  Previous studies have shown that 
a variety of other factors have been shown to effect the toxicity of PRIMA-1, including 
but not limited to, cell type, cell density, gain-of-function properties, and presence of 
siRNAs (126, 127).  This suggests that in MCF10As (and potentially other breast cells) in 
order for PRIMA-1 to effectively restore p53 function, a second mutation may be 
required.  These secondary mutations may impart varying degrees of sensitivity or 
resistance that result in drug-specific tumor heterogeneity. 
 Another example of drug-specific tumor heterogeneity was observed when the 
panel was exposed to 15 nM of Doxorubicin in 6 wells for one week.  Doxorubicin is an 
anthracyclin antibiotic and is classified as a topoisomerase II inhibitor (124).  
Doxorubicin is also capable of other cellular effects such as DNA intercalation, inhibition 
of DNA ligases, helicases, and other DNA dependent proteins, radical generation, and 
DNA damage (128).  Although doxorubicin is a commonly used chemotherapy, the 
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mechanisms of selectivity and/or resistance are still not well understood.  Within the 
panel, varying degrees of cell viability were observed.  However, most notable were two 
clones that seemed to exhibit increased resistance, the single mutant TP53 KO and the 
double mutant KO_9 (Fig 4.5)  Interestingly, the same level of resistance was not 
observed for KO_20.  Again, the panel allows the observation of a set of closely related 
cell lines with different mutations and different degrees of genomic instability.  Further 
analysis of clones exhibiting increased resistance or susceptibility may identify secondary 
mutations and provide a better understanding behind drug sensitivity and resistance.   
 
MCF10As harboring a PIK3CA mutation, regardless of TP53 status exhibit a 
Paclitaxel-specific susceptibility.  The double mutant panel was further utilized in the 
drug studies to identify potential predictive markers.  Ideal drug candidates would be 
effective, FDA approved chemotherapies which have limited known predictive markers.  
In this assay we utilized a class of widely-used chemotherapies known as Taxanes.  
Taxanes are a group of drugs that disrupt microtubule function and inhibit mitosis.  
Along with anthracyclines, taxanes are the most active and widely used chemotherapeutic 
agents either alone or in combination (129). However, due to their increase use, often 
recurrent disease is resistant and currently no valid predictive biomarkers exist.  The 
panel was exposed to a high concentration, bolus dose for 24 hrs as well as a low 
concentration, steady dose for 1 week in order to mimic the two different clinical dosing 
methods.  Within the panel, it was demonstrated that breast epithelial cells with TP53 
mutations showed varying degrees of unaffected viability, indicating a potential for 
resistance.  However, in the presence of a PIK3CA mutation, regardless of TP53’s 
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mutational status, there was a significant (**p<.01) decrease in viability (Fig 4.6).  This 
was observed for both the continuous and bolus dosages.   
In order to determine if this was paclitaxel specific or observable within the entire 
class of taxanes, a second taxane, Docetaxel was administered to the panel.  Again both a 
high bolus dose for 24 hrs, as well as a low, continuous dose for 1 week was applied to 
the cells.  However, unlike the paclitaxel, there was no significant differences observed 
within the panel of single and double mutant cell lines (Fig 4.7).  This suggests that the 
presence of a PIK3CA mutation, regardless of TP53 status, may provide a predictive 
biomarker for increased response specifically for paclitaxel.  Contrary to this finding, 
previous studies have proposed a potential link between increased AKT activity and 
paclitaxel resistance (130).  However, most of these studies are retrospective analysis of 
multidrug clinical samples and therefore, adequate controls are not provided. 
 
MCF7s with a wild type corrected PIK3CA mutation exhibit Paclitaxel-specific 
resistance.  In order to determine if the relationship of paclitaxel-susceptibility and the 
presence of a PIK3CA mutation could be observed in a cancer background, MCF7s 
harboring a somatic PIK3CA Ex. 9 mutation (MCF7s) and an isogenically modified 
PIK3CA WT (Corrected) (131) were analyzed.  As with the MCF10A derivatives, IC50 
curves for both paclitaxel and docetaxel were carried out on the MCF7 and Corrected cell 
lines.  As seen with the MCF10A derivatives in the double mutant panel, MCF7s 
harboring a PIK3CA mutation showed an overall decrease in viability in the presence of 
paclitaxel across a 10-fold change in concentration (Fig 4.8A).  However, in the presence 
of another taxane, docetaxel, the same susceptibility was not observed (Fig 4.8B).  
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Similar to the MCF10A derivatives, an ideal concentration was selected for both a high 
bolus dose for 24 hrs, as well as a low, continuous dose for 1 week.  In the presence of 
Paclitaxel, both dose administration models exhibited a significant (**p < .01) decrease 
in viability in the presence of a PIK3CA Ex.9 mutation (Fig 4.9).  This coincides with the 
results observed with the double mutant panel.  Similarly, there was no significant 
difference in viability among the MCF7s and Corrected cell lines when exposed to 
docetaxel, regardless of dosing model (Fig. 4.10). 
 
Discussion 
 Drug resistance continues to be a major problem in the successful treatment of 
human cancers.  Due to the inherent genetic instability and heterogeneity of human 
cancers, virtually all therapies have exhibited drug resistance.  A significant mechanism 
of drug resistance is due to the clonal selection of somatic genetic alterations which lead 
to increasingly severe phenotypes in the presence of drugs (132).  In this study, we 
utilized a panel of relatively isogenic cell lines in which we successfully incorporated 
genomic instability and modeled heterogeneity to provide a preliminary system for 
understanding and predicting drug response.  The developed panel provides a biologically 
relevant model of tumor heterogeneity and clonal variability among a closely related set 
of cell lines. 
 Using the panel of cell lines a small cohort of chemo- and targeted therapies were 
explored.  Within the cohort some drugs (Table 4.1) showed little to no difference 
between the different mutations within the panel.  Drugs such as cisplatin, a platinum 
based drug which binds DNA bases and leads to apoptosis, were designed as nonselective 
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chemotherapies and showed no differences among the panel.  These drugs were quickly 
eliminated from the study.  Surprisingly, some previously developed and approved 
targeted therapies did not behave as expected.  BYL719, a PI3K inhibitor involved in 
phase 1 clinical trials, was expected to specifically target cells harboring a PIK3CA 
mutation and lead to decrease viability (SI Fig. 5).  However, within the panel only two 
clones containing a PIK3CA mutation showed increase viability suggesting that the 
BYL719 targeted therapy is significantly affected by clonal variability and secondary 
mutations.  This would further suggest that BYL719 is not a reliable targeted therapy and 
may lead to increased rates of therapy failure due to the high variability exhibited within 
the panel.  The use of several closely related but separately derived clones for the 
screening of novel, targeted therapies helps to eliminate the potential for misinterpreting 
drug functionality.  Similarly, Everolimus, an mTOR inhibitor, showed no selective 
toxicity despite the panel containing several cells with upregulated mTOR activity.  
These drugs were not discussed in the results section and can be found in the Appendices 
(SI Figure 5). 
 The expected utility of the panel is the identification and confirmation of novel 
viable targeted therapies.  In order to demonstrate this utility, the panel was exposed to a 
set of drugs that were previously developed and expected to target and exploit the 
incorporated mutations.  As anticipated, when the panel was exposed to MK2206, an 
AKT inhibitor, all cell lines harboring a PIK3CA mutation experienced a significant 
decrease in viability.  In concordance with the developed panel, it was previously 
reported that breast cancers with PI3K mutations were sensitive to AKT inhibition (133).  
The increased efficacy of MK2206 for tumors harboring a PIK3CA mutation both in vitro 
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and in vivo implicates that trends observed within the panel may be directly applicable to 
the clinical setting (134).  Furthermore, the success of MK2206 in vivo suggests that the 
panel may be able to accurately identify drugs affecting specific biomarkers, such as 
PIK3CA mutations. 
 Another important factor in determining molecular biomarkers for drug response 
is tissue type and genetic variants.  When the panel was exposed to PRIMA-1, a TP53 
R248W targeting drug, results revealed that in a relatively normal background, PRIMA-1 
had no effect on viability of cells harboring the TP53 R248W hotspot.  However, in the 
context of a PIK3CA mutation, cells showed a marginal decrease in viability.  Previous 
studies with PRIMA-1 were performed using two cancer cell lines, MCF7 and T47Ds 
which harbor thousands of SNPs when compared to a ‘normal’ genome.  Among these 
differences, the two cell lines harbor a PIK3CA Ex.9 and Ex.20 mutation, respectfully 
(135).    It is tempting to speculate that PRIMA-1’s function is dependent on the presence 
of a PIK3CA mutation, based on the panel of cell lines and previous studies.  By 
providing a relatively isogenic background within the panel, this potential relationship 
was easily observed.  However, this cannot be concluded without further extensive 
studies.  It does provide convincing evidence that the panel of cell lines is capable of 
identifying additional biomarkers of resistance and susceptibility for targeted therapies, 
and provides a greater opportunity for developing more individualized therapies based on 
how a drug will respond to variations in the genetic composition of a tumor. 
 A novel application of the panel is the ability to identify potential biomarkers of 
current nonselective chemotherapies.  Paclitaxel, a nonselective chemotaxane, continues 
to be one of the most commonly used drugs for treating breast cancer and metastatic 
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disesase (130).  However, to date, there are not predictive biomarkers and a significant 
portion of patients eventually show increased resistance.  The ability to successfully 
identify a potential biomarker of paclitaxel would help predict response and potentially 
prevent increased resistance and metastatic recurrence.  Furthermore, identifying a 
predictive marker for paclitaxel would provide a better ability for selecting personalized 
therapeutic options based on the genetic components of the primary disease.  Using the 
panel of cell lines we were able to determine that the presence of PIK3CA, regardless of 
TP53 status, may provide a predictive biomarker for increased susceptibility to paclitaxel.  
Furthermore, in the absence of PIK3CA, it could be hypothesized based on observed 
trends, that there was an increase in resistance in the TP53 KOs.  This would suggest that 
tumors harboring a TP53 homozygous deletion may respond better to other 
chemotherapies, while tumors harboring a second mutation in PIK3CA would be a 
candidate for paclitaxel.  Additionally, this relationship was not observed with docetaxel, 
another chemotaxane, suggesting that the observed relationship is specific to paclitaxel. 
The relationship between the presence of PIK3CA and paclitaxel susceptibility was 
further validated in cancer cell line model, MCF7.  MCF7s inherently contain four 
PIK3CA alleles, two of which harbor an E545K mutation.  Both mutations were 
genetically targeted and corrected back to WT.  In the presence of four WT PIK3CA 
alleles, corrected MCF7s showed an increase in paclitaxel resistance. As a cancer cell 
line, MCF7 is considerably less stable than MCF10A and contains a higher number of 
SNPs, CNV, and secondary mutations.  Observing the same relationship between 
PIK3CA and paclitaxel susceptibility within a less stable, cancer model suggests that the 
relationship is unaffected by the presence of other mutations.  
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Previous studies have contradicted our observations and suggested that inhibition 
of the PIK3CA pathway lead to an increase to paclitaxel response.  However these 
studies, both in vivo and in vitro, were flawed in several ways (130, 136).  Within the in 
vitro study, the overexpression of the PI3K pathway, rather than the incorporation of a 
biologically relevant mutation makes it difficult to apply in vivo.  As previously 
discussed, overexpression models produce protein levels significantly higher than those 
observed in vivo and therefore are not accurate for modeling clinical outcomes.  
Secondly, the study was performed in ovarian cell lines which may elicit a tissue-specific 
response.  Lastly, the study was performed in the presence of multiple drugs, making it 
difficult to attribute observed outcomes to a single component.  Similarly, in the clinical 
setting, paclitaxel is often combined with doxorubicin or other common chemotherapies 
during treatment.  Therefore, it is difficult to assess the effect of paclitaxel as an 
individual component in a clinical setting. 
This study presents the panel of developed cell lines as an invaluable tool in the 
development and screening of effective therapies.  It provides an accurate model of tumor 
heterogeneity, a significant problem in drug resistance, and allows us to predict, with 
increased certainty, the response to current and novel drugs.  Furthermore, the utility of 
this panel suggests that current drug development and screening should adopt panels 
modeling several different mutations and permutations, with each combination modeling 
two or more individually derived clones.  This would allow for increased opportunities 
for individualized medicine and account for the genetic components of a tumor when 




Table 4.1: Drug Concentrations 
Drug Target IC50 
BYL719 PIK3CA inhibitor 1.5 uM 
Docetaxel Chemo Taxane 60 pM 
Doxorubicin Chemo 15 nM 
Everolimus mTOR inhibitor 0.25 uM 
Gefitinib EGFR Inhibitor 0.25 uM 
Lapatinib EGFR/Her2 inhibitor 0.25 uM 
MK2206 AKT inhibitor 1.5 uM 
Paclitaxel Chemo Taxane 2.5 nM 



















Table 4.2: Taxane Concentrations 
Drug Low Dosage, 1 week High Dosage, 24hr 
                                                            MCF10A Derivatives 
Paclitaxel 2.5 nM 10 nM 
Docetaxel 60 pM 350 pM 
                                                               MCF7 Derivatives 
Paclitaxel 1.2 nM 7 nM 
Docetaxel 25 pM 125 pM 


























Materials and Methods 
 
Cell Culture.  Cell lines were grown in 5% CO2 at 37 oC The non-transformed human breast 
epithelial cell line MCF-10A (84) and its derivatives were grown in DMEM/F12 (1:1) 
supplemented with 5% horse serum (Hyclone), EGF at 20 ng/ml, insulin at 10 μg/ml, 
hydrocortisone at 0.5 μg/ml, and cholera toxin at 0.1 μg/ml (hereafter denoted as ‘‘supplemented 
DMEM/F12’’). Cell lines with gene targeted PIK3CA mutations were grown in supplemented 
DMEM/F12 media without EGF due to the observation that when chronically grown in media 
supplemented with EGF, these cell lines become paradoxically growth-dependent on EGF.  
Retroviral infected cells were grown in supplemented DMEM/F12 media with 120ng/ml G418.  
All assays were performed in Supplemented DMEM/F12 containing 1% charcoal dextran-treated 
fetal bovine serum instead of 5% horse serum.  “Supplemented Assay media” contained varying 
EGF conditions of .02ug/ml, .0002ug/ml and 0ug/ml as indicated.  All supplements were 
purchased from Sigma-Aldrich unless otherwise noted.  Cell lines and their corresponding media 
conditions are listed in Table 5.1. 
 
Targeted knock in of oncogenic TP53 hotspot mutation.  A promoterless gene targeting vector 
was previously designed and generously provided by Bert Vogelstein.  Targeted knock in of the 
TP53 R248W point mutation into MCF-10As was conducted as previously described (137).   
Briefly, the targeting vector was transduced into cells and G418 (Invitrogen) antibiotic selection 
was performed at 120 ug/mL in 96-well plates.  Transduced colonies expressing Neomycin 
resistance were expanded, replicated, and then pooled as previously described (59). Targeted cells 
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were identified using PCR and infected with adenovirus-encoding Cre recombinase to remove the 
Neomycin selection cassette.  Selected cells were single cell diluted and screened for successful 
Cre recombination.  Knock in clones were determined to be single targeted homologous 
integrants with equal expression of mutant and wild type TP53 through PCR and direct 
sequencing of both the gDNA and cDNA.  Single stranded cDNA was generated using First 
Strand cDNA Synthesis Kit (Amersham Biosciences) following the manufacturer’s directions.  
Primer sequences for PCR amplification and sequencing are shown in Table 2.1 and 2.2  
 
Targeted knock in of oncogenic PIK3CA mutations.  Promoterless gene targeting vectors were 
previously designed in the lab such that homologous recombination would introduce a single 
oncogenic mutation within PIK3CA [3].   Targeted knock in of PIK3CA exon 9 (E545K) and 
exon 20 (H1047R) mutations into MCF-10A cells already carrying a heterozygous TP53 R248W 
knock in mutation or MCF-10A cells carrying a homozygous TP53 deletion in exon 2 were 
conducted as described in the previous section.  Primer sequences for PCR amplification and 
sequencing are shown in Table 3.1 and 3.2 
 
Cell Proliferation Assay.  For cell proliferation assays, exponentially growing cells were washed 
with HBSS and seeded at a density of 1x103 cells/mL in 6 well plates.  Cells were assayed in 
supplemented DMEM/F12 medium with 1% charcoal dextran-treated fetal bovine serum with 
varying EGF conditions of .02ug/ml, .0002ug/ml and 0ug/ml.  At days 0, 3, 6, 9, and 12 cells 







Matrigel Aaar Formation Assay.  5,000 cells were seeded into 8-well chamber slides containing 
a solid-form base layer of Growth Factor Reduced Matrigel (BD Biosciences).   Cells were 
cultured in a 2% matrigel in supplemented DMEM/F12 assay medium with 1% charcoal dextran-
treated fetal bovine serum with varying EGF conditions of .02ug/ml, .0002ug/ml and 0ug/ml.  
The 2% matrigel in supplemented assay media was changed every 4 days for two weeks. 
 
Ancorage Independent Growth in Semisolid Medium.  2x104 exponentially growing cells were 
cast in 3 ml of top-layer medium comprised of supplemented assay media of varying EGF 
conditions of .02ug/ml, .0002ug/ml and 0ug/ml and 0.4% UltraPure Agarose (Invitrogen).  This 
mixture was poured on top of a 2 ml bottom layer containing 0.6% agarose in 6-well tissue 
culture plates. Supplemented DMEM/F12 was added to the wells once a week. 
 
Clonogenic Assay.  Cells were seeded in triplicate at densities of .5, 1, 2, and 3 cells/well 
into 96-well plates with supplemented DMEM/F12 assay medium with 1% charcoal 
dextran-treated fetal bovine serum with varying EGF conditions of .02ug/ml and 
.0002ug/ml.  Media was changed weekly and plates were monitored on days 7, 14, 21, 
and 28 for colony formation.   
 
Centrosome Immunofluorescence.  Cells were seeded at 1 x105 density into 8-well chamber 
slides and allowed to grow for two days.  Slides were washed with ice cold PBS and fixed in cold 
methanol for 15 min at -20 oC.  Slides were then incubated in ice cold acetone for 1 min at room 
temperature.  Following several washes with ice cold PBS, slides were treated with a blocking 
buffer (5% goat serum in .3% Triton X-100) for 2 hr at room temperature.  Slides were then 
treated with a 1:1000 dilution of rabbit anti-ɣ-tubulin primary antibody (Sigma, T5192) in an 
antibody dilution buffer (.3% Triton X-100 in PBS supplemented with 1% BSA) for 1 hr at room 
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temperature.  Slides were washed several times in a PBS supplemented with 1% BSA wash 
buffer.  A 1:100 dilution of goat anti-rabbit IgG-Alexa488 secondary body (Life, A11034) in 
antibody dilution buffer was added to the slides for 25 min at room temperature.  The slides were 
then washed several times with wash buffer, followed by a single wash with HBSS.  Slides were 
stained with a 1:200 dilution of Texas Red-X-Conjugate Wheat Germ Agglutinin (Life, W21405) 
for 5min, followed by several washes with wash buffer.  A 1x DAPI stain (Sigma, D9542-SMG) 
was added for 1 min.  Slides were mounted with Prolong Gold and imaged using a Nikon 
fluorescence microscope and NIS-Elements BR 2.30 imaging program.  
 
Fluorescence In Situ Hybridization (FISH).  Cells were seeded at 3 x104 density into 8-well 
chamber slides and allowed to grow to 90% confluency.  Cells were fixed overnight in a 10% 
buffered formalin solution and allowed to dry at bench top the following day.  Slides were then 
treated with 2N HCl for 20 mins and treated with the Vysis Pretreatment Kit I.  Briefly, slides are 
washed with a 2x SSC buffer and incubated in the provided pretreatment buffer at 80 oC for 30 
min.  Slides were rinsed in diH2O and washed with 2x SSC buffer.  The slides were then placed 
in a Protease Buffer (NaCl pH 2.0 with 25 mg Protease provided in the kit) at 37 oC for 8 min.  
Pretreated slides were then washed with 2x SSC buffer and fixed in 10% buffered formalin for 10 
min.  Proceeding the pretreatment slides were dehydrated through a series of ethanol baths and 
allowed to age at bench top for two weeks.  Slides were then hybridized with various vysis probes 
at 95 oC for 5 min and incubated at 37 oC for 48 hrs.  Slides were then treated with a .3% NP-40 
(IGEPAl)  at 75 oC, counter stained with DAPI (1:10,000) and sealed with Prolong Gold 
(Invitrogen, P36930).  Slides were imaged using a Nikon fluorescence microscope and NIS-
Elements BR 2.30 imaging program.  
 
Reverse Phase Protein Array (RPPA).  Cells were prepared and submitted to MD Anderson 
Cancer Center RPPA Core Facility for RPPA analysis.  RPPA analyzes cellular protein activity in 
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signaling networks and can be applid to both tissue and cultured cells.  Briefly, cells were seeded 
at 2x10 5 cells in 6 well plates using EGF-free supplemented DMEM/F12 assay medium with 1% 
charcoal dextran-treated fetal bovine serum.  Cells were harvested after 48 hours for protein 
lysates.  Whole cell protein extracts were lysed using lysis buffer and prepared in provided 4X 
SDS sample buffer.  Cellular proteins were denatured by 1% SDS with beta-mercaptoethanoland 
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial 
diluted lysates were arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 
Arrayer (Aushon BioSystems).  A total of 5808 array spots were arranged on each slide including 
the spots corresponding to positive and negative controls prepared from mixed cell lysates or 
dilution buffer, respectively. Each slide was probed with a validated primary antibody plus a 
biotin-conjugated secondary antibody. Only antibodies with a Pearson correlation coefficient 
between RPPA and western blotting of greater than 0.7 were used in reverse phase protein array 
study. The signal obtained was amplified using a Dako Cytomation–catalyzed system (Dako) and 
visualized by DAB colorimetric reaction. The slides were scanned, analyzed, and quantified using 
a customized-software Microvigene (VigeneTech Inc.) to generate spot intensities. Each dilution 
curve was fitted with a logistic model (“Supercurve Fitting” developed by the Department of 
Bioinformatics and Computational Biology at MD Anderson Cancer Center, 
“http://bioinformatics.mdanderson.org/OOMPA”). The protein concentrations of each set of 
slides were then normalized by median polish. 
    
Immunoblotting.  Cells were seeded in 6 well plates using EGF-free supplemented DMEM/F12 
assay medium with 1% charcoal dextran-treated fetal bovine serum.  Cells were harvested after 
48 hours for protein lysates.  Immunoblotting was performed as previously described (138).  
Briefly, whole cell protein extracts prepared in Laemmli sample buffer were resolved by SDS-
PAGE using NuPAGE gels (Invitrogen), transferred to Invitrolon PVDF membranes (Invitrogen), 
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and probed with primary antibody followed by incubation with horseradish peroxidase-
conjugated secondary antibodies. The primary antibodies can be found in Table 5.2 
 
Cell Cycle Analysis.  Previously plated cells were washed and resuspended in ice cold 
PBS and added dropwise to 70% ethanol.  Cells were incubated at -20C overnight for 
ethanol fixation.  The following day, cells were pelleted and washed with cold PBS and 
resuspended in Propidium Iodide (500 µ/ml) in .1% Triton in PBS.  Cells were analyzed 
by a flow cytometer in the Hopkins FACS Core. 
 
Knockdown of NDRG1 in human cell lines.  NDRG1 Knockdown cell lines were a 
generous gift from the Sushant Kachhap Lab.  Briefly, ShRNA vectors were generated 
using a U6 promoter based vector and used to target the NDRG1 region 304-331 bases to 
give maximum knockdown.  shRNA constructs were transfected into MCF10As using 
Lipofectamine2000 Reagent (Invitrogen) and knock down of expression was confirmed 
24, 48 and 72 h post-transfection using western blotting. 
 
 
Overexpression of NDRG1 in human cell lines.  Cells were grown to 30-40% 
confluency in antibiotic free medium.   A pCMV6-Entry vector expressing Human 
NDRG1 (Origene RC225609) was used with the Fugene 6 system to transfect cell lines 
according to the provided protocol.  For transient transfections in the HCT116 TP53 KO 
cell line cells were plated for assays 24-48 hrs after transfection.  Stable transfections in 
the MCF10A TP53 KOs were placed on selection 24-48 hours after transfection and 
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maintained for 2-3 weeks until stable overexpression was established.  All overexpressing 
transfections were confirmed using Western blots. 
 
Clinical Analysis of NDRG1 expression in tumors with TP53 homozygous deletion. 
Data from the TCGA study was accessed through the cBio Cancer Genomics Portal 
(http://www.cbioportal.org/public-portal/).  Only studies with both mRNA and 
mutational data were included in the analysis.  Studies were queried for both TP53: 
HOMDEL and NDRG1: EXP > 2.  Oncoprints and case information for each study were 
collected, analyzed and compiled.   
 
Proximity Ligation Assay.  Cells were seeded in chamber slides and allowed to grow for 
24 hours.  Slides were fixed the same as in the previously discussed centrosome assay.  
The proximity Ligation Assay was carried out using the Sigma DuoLink PLA reagents 
and provided protocol.  Total NDRG1 in Rabbit (Cell Signaling XP 9485) at 1:200 and γ-
Tubulin in Mouse (Sigma, GTU-88) 1:1000 were incubated overnight.  Antibodies are 
listed in Table 5.2 
 
Chromatin Immunoprecipitation (ChIP).  Chromatin Immunopreciptiation was carried 
out using the EZ-ChIP Millipore Kit and protocol.  The Santa Cruz p53 (DO-1): sc126 
antibody (listed in Table 5.2) was used for protein pulldown.  Primers for the putative 
p53 binding sites on the NDRG1 promoter were adapted from previously published 




In Vivo Assay.  In vivo assays were performed using 10-week-old athymic nude female mice 
(Taconic), which were randomly distributed into equal groups (6 mice per group) for each 
experiment. Mice were injected subcutaneously in the right flank with 2x106 cells of all 
developed double mutant clones. Cells were prepared in a mixture of 80% growth factor reduced 
Matrigel and 20% 1X PBS. Mice were not supplemented with estrogen pellets. The National 
Institutes of Health Guide for the Care and Use of Laboratory Animals was followed in all 
experiments. 
 
Copy Number Variance and Loss of Heterozygosity.  Using the Illumina Human OmniExpress 
Bead Chip kit (Illumina, WG-312-3001), single and double mutant cell lines were analyzed for 
global chromosomal changes, including copy number variance (CNV) and loss of heterozygosity 
(LOH), when compared to the parental MCF10A cell line. 
 
Drug Sensitivity Assay.  Initially, Cells were seeded at a density of 1x103 cells/mL in 96 well 
plates with supplemented assay media containing no EGF.  After 24 hours, cells were exposed to 
serial dilutions of several different drugs (listed in Table 4.1 and 4.2) and allowed to incubate for 
one week.  Drugs were administered in supplemented assay media containing 1/100th EGF.  
Equivalent concentrations of DMSO were used as vehicle controls.  Plates were then analyzed on 
day 7 using the SRB assay.  Briefly, cells were fixed with 50% Trichloroacetic Acid (TCA) and 
incubated at 4 oC for 1 hour.  Per standard protocol, TCA was removed and plates were rinsed 
with deionized water, dried, and treated with .4% Sulforhodoamine B in 1% glacial acetic acid at 
25 oC for 15 minutes.  Plates were rinsed with 1% glacial acetic acid, dried and resolubilized with 
10 mM Tris Base.  Plates were read by a microplate reader at a wavelength of 515 nm.  Once an 
IC50 was established, cells were seeded 2x103 cells into 6 well plates and exposed to drugs at a 
concentration determined from the IC50 curves.  Cells were counted on Day 7.  Each cell line 
98 
 
was run in triplicate and compared to individual vehicle controls with equivalent concentrations 
of DMSO.  
 
Statistical Considerations.  All statistical analyses were carried out using GraphPad Prism 6 
software with P value significant level indicated using one or more asterisks: P ≤ 0.05 (*),P ≤ 
0.01 (**) and P ≤ 0.001 (***). Relative proliferation rates were analyzed by two-way ANOVA. 
Results from the clonogenic assay, ChIP, FISH and centrosome immunofluorescence experiments 
were compared to control samples using unpaired t-tests. 
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Table 5.1:  Tissue Culture Mediums 
Cell Line Full Growth Media Conditions 
MCF10A, TP53 KIs,  
TP53 KOs 
SUPPLEMENTED DMEM/F12:  Duibecco’s modified eagle 
medium-F12 media with 5% heat-inactivated horse serum, 
.1ug/ml cholera toxin, .5ug/ml hydrocortisone, .02ug/ml EGF, 
10ug/ml insulin, 1% penicillin and streptomycin 
PIK3CA KIs 
EGF FREE MEDIA: Duibecco’s modified eagle medium-F12 
media with 5% heat-inactivated horse serum, .1ug/ml cholera 
toxin, .5ug/ml hydrocortisone, 10ug/ml insulin, 1% penicillin and 
streptomycin 
 
Double Mutant cell lines 
After isolation cells were transitioned from Supplemented media 
to EGF Free media 
ASSAY Conditions 
Assay medias replace 5% horse serum w/ 1% charcoal-stripped 




Table 5.2: Protein Antibodies 
Protein Target Supplier Assay Dilution 
p53 Santa Cruz Sc-126 ChIP 1:100 
pNDRG1 Cell Signaling XP 5482S 
Western  1:5000 
PLA 1:400 
Total NDRG1 Cell Signaling XP 9485S 
Western 1:1000 
PLA 1:100 
γ-Tubulin Sigma T5192  Centrosome 1:1000 
γ-Tubulin Sigma T6557 PLA 1:500 
p-AKT Cell Signaling 9271 Western 1:1000 
Total AKT Cell Signaling 9272 Western 1:5000 
p-ERK Cell Signaling XP 4370 Western 1:5000 
Total ERK Cell Signaling 9102 Western 1:10,000 
p-p90RSK Cell Signaling 9341 Western 1:150 
Total p90RSK Cell Signaling 9333 Western 1:1000 
p-p70S6K Cell Signaling 9205 Western 1:1000 
Total p70S6k Cell Signaling 9202 Western 1:1000 
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